BACKGROUND: National initiatives offering non-nucleoside reverse transcriptase inhibitor (NNRTI)-based combination antiretroviral therapy (cART) have expanded in sub-Saharan Africa. The Tshepo study is the first clinical trial evaluating the long-term efficacy and tolerability of efavirenz versus nevirapine-based cART among adults in Botswana. METHODS: A 3-year randomized study (n = 650) using a 3 x 2 x 2 factorial design comparing efficacy and tolerability among: (i) zidovudine/lamivudine versus zidovudine/didanosine versus stavudine/lamivudine; (ii) efavirenz versus nevirapine; and (iii) community-based supervision versus standard adherence strategies. This paper focuses on comparison (ii). RESULTS: There was no significant difference by assigned NNRTI in time to virological failure with resistance (log-rank P = 0.14), nevirapine versus efavirenz [risk ratio (RR) 1.54, 95% CI 0.86-2.70]. Rates of virological failure with resistance were 9.6% nevirapine-treated (95% CI 6.8-13.5) versus 6.6% efavirenz-treated (95% CI 4.2-10.0) at 3 years. Women receiving nevirapine-based cART trended towards higher virological failure rates when compared with efavirenz-treated women, Holm-corrected (log-rank P = 0.072), nevirapine versus efavirenz (RR 2.22, 95% CI 0.94-5.00). A total of 139 patients had 176 treatment-modifyingtoxicities, with a shorter time to event in nevirapine-treated versus efavirenz-treated patients (RR 1.85, 1.20-2.86; log-rank P = 0.0002). CONCLUSION: Tshepo-treated patients had excellent overall immunological and virological outcomes, and no significant differences were observed by randomized NNRTI comparison. Nevirapine-treated women trended towards higher virological failure with resistance compared with efavirenz-treated women. Nevirapine-treated adults had higher treatment modifying toxicity rates when compared with those receiving efavirenz. Nevirapine-based cART can continue to be offered to women in sub-Saharan Africa if patient education concerning toxicity is emphasized, routine safety monitoring chemistries are performed and the potential risk of efavirenz-related teratogenicity is considered.
RCT Entities:
BACKGROUND: National initiatives offering non-nucleoside reverse transcriptase inhibitor (NNRTI)-based combination antiretroviral therapy (cART) have expanded in sub-Saharan Africa. The Tshepo study is the first clinical trial evaluating the long-term efficacy and tolerability of efavirenz versus nevirapine-based cART among adults in Botswana. METHODS: A 3-year randomized study (n = 650) using a 3 x 2 x 2 factorial design comparing efficacy and tolerability among: (i) zidovudine/lamivudine versus zidovudine/didanosine versus stavudine/lamivudine; (ii) efavirenz versus nevirapine; and (iii) community-based supervision versus standard adherence strategies. This paper focuses on comparison (ii). RESULTS: There was no significant difference by assigned NNRTI in time to virological failure with resistance (log-rank P = 0.14), nevirapine versus efavirenz [risk ratio (RR) 1.54, 95% CI 0.86-2.70]. Rates of virological failure with resistance were 9.6% nevirapine-treated (95% CI 6.8-13.5) versus 6.6% efavirenz-treated (95% CI 4.2-10.0) at 3 years. Women receiving nevirapine-based cART trended towards higher virological failure rates when compared with efavirenz-treated women, Holm-corrected (log-rank P = 0.072), nevirapine versus efavirenz (RR 2.22, 95% CI 0.94-5.00). A total of 139 patients had 176 treatment-modifying toxicities, with a shorter time to event in nevirapine-treated versus efavirenz-treated patients (RR 1.85, 1.20-2.86; log-rank P = 0.0002). CONCLUSION: Tshepo-treated patients had excellent overall immunological and virological outcomes, and no significant differences were observed by randomized NNRTI comparison. Nevirapine-treated women trended towards higher virological failure with resistance compared with efavirenz-treated women. Nevirapine-treated adults had higher treatment modifying toxicity rates when compared with those receiving efavirenz. Nevirapine-based cART can continue to be offered to women in sub-Saharan Africa if patient education concerning toxicity is emphasized, routine safety monitoring chemistries are performed and the potential risk of efavirenz-related teratogenicity is considered.
Authors: Olivia Keiser; Jacques Fellay; Milos Opravil; Hans H Hirsch; Bernard Hirschel; Enos Bernasconi; Pietro L Vernazza; Martin Rickenbach; Amalio Telenti; Hansjakob Furrer Journal: Antivir Ther Date: 2007
Authors: Shahin Lockman; Roger L Shapiro; Laura M Smeaton; Carolyn Wester; Ibou Thior; Lisa Stevens; Fatima Chand; Joseph Makhema; Claire Moffat; Aida Asmelash; Patrick Ndase; Peter Arimi; Erik van Widenfelt; Loeto Mazhani; Vladimir Novitsky; Stephen Lagakos; Max Essex Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245
Authors: Jeffrey S A Stringer; Isaac Zulu; Jens Levy; Elizabeth M Stringer; Albert Mwango; Benjamin H Chi; Vilepe Mtonga; Stewart Reid; Ronald A Cantrell; Marc Bulterys; Michael S Saag; Richard G Marlink; Alwyn Mwinga; Tedd V Ellerbrock; Moses Sinkala Journal: JAMA Date: 2006-08-16 Impact factor: 56.272
Authors: F Maggiolo; M Migliorino; A Pirali; G Pravettoni; S Caprioli; F Suter Journal: J Acquir Immune Defic Syndr Date: 2000-09-01 Impact factor: 3.731
Authors: Hermann Bussmann; C William Wester; Carolyn N Wester; Bright Lekoko; Okechukwu Okezie; Ann Muir Thomas; S M Victor DeGruttola; Joseph Makhema; Max Essex; Richard G Marlink Journal: J Acquir Immune Defic Syndr Date: 2007-07-01 Impact factor: 3.731
Authors: C William Wester; Okechukwu A Okezie; Ann Muir Thomas; Hermann Bussmann; Sikhulile Moyo; Tanaka Muzenda; Joseph Makhema; Erik van Widenfelt; Rosemary Musonda; Vladimir Novitsky; Tendani Gaolathe; Ndwapi Ndwapi; Max Essex; Daniel R Kuritzkes; Victor DeGruttola; Richard G Marlink Journal: J Acquir Immune Defic Syndr Date: 2007-11-01 Impact factor: 3.731
Authors: Jean B Nachega; Michael Hislop; David W Dowdy; Joel E Gallant; Richard E Chaisson; Leon Regensberg; Gary Maartens Journal: AIDS Date: 2008-10-18 Impact factor: 4.177
Authors: Mary van den Berg-Wolf; Katherine Huppler Hullsiek; Grace Peng; Michael J Kozal; Richard M Novak; Li Chen; Lawrence R Crane; Rodger D Macarthur Journal: HIV Clin Trials Date: 2008 Sep-Oct
Authors: C William Wester; Ori M Stitelman; Victor deGruttola; Hermann Bussmann; Richard G Marlink; Mark J van der Laan Journal: AIDS Res Hum Retroviruses Date: 2012-03-23 Impact factor: 2.205
Authors: Thabo Diphoko; Simani Gaseitsiwe; Ishmael Kasvosve; Sikhulile Moyo; Harriet Okatch; Rosemary Musonda; Mark Wainberg; Joseph Makhema; Richard Marlink; Vladimir Novitsky; Max Essex Journal: AIDS Res Hum Retroviruses Date: 2018-06-12 Impact factor: 2.205
Authors: C William Wester; John R Koethe; Bryan E Shepherd; Samuel E Stinnette; Peter F Rebeiro; Aaron M Kipp; Hwanhee Hong; Hermann Bussmann; Tendani Gaolathe; Catherine C McGowan; Timothy R Sterling; Richard G Marlink Journal: AIDS Date: 2011-07-31 Impact factor: 4.177
Authors: Eric N Ouattara; Xavier Anglaret; Angela Y Wong; Jennifer Chu; Heather E Hsu; Christine Danel; Serge Eholié; Raoul Moh; Delphine Gabillard; Rochelle P Walensky; Kenneth A Freedberg Journal: AIDS Date: 2012-03-13 Impact factor: 4.177
Authors: C William Wester; Svetlana K Eden; Bryan E Shepherd; Hermann Bussmann; Vladimir Novitsky; David C Samuels; Sher L Hendrickson; Cheryl A Winkler; Stephen J O'Brien; Max Essex; Richard T D'Aquila; Victor DeGruttola; Richard G Marlink Journal: AIDS Res Hum Retroviruses Date: 2012-06-01 Impact factor: 2.205
Authors: Lawrence Mbuagbaw; Sara Mursleen; James H Irlam; Alicen B Spaulding; George W Rutherford; Nandi Siegfried Journal: Cochrane Database Syst Rev Date: 2016-12-10
Authors: Bethan McDonald; Sikhulile Moyo; Lesego Gabaitiri; Simani Gaseitsiwe; Hermann Bussmann; John R Koethe; Rosemary Musonda; Joseph Makhema; Vladimir Novitsky; Richard G Marlink; C William Wester; Max Essex Journal: AIDS Res Hum Retroviruses Date: 2013-05-09 Impact factor: 2.205